Previous studies of fXa inhibitor-related bleeding reversal have observed similar efficacy rates as this study (range: 72.4–85%), although most describe single-center efforts with low patient enrollment rates and no comparator group.8,15,19,20 The largest retrospective cohort study to date included 663 patients with intracranial hemorrhage, of whom 433 were evaluated for hemostatic efficacy.8 Within this patient cohort, efficacy was deemed excellent or good (according to hematoma expansion ≤20% or 20.1–35%, respectively) in 81.8% of patients. The gene discussed is F10; the disease is intracranial hemorrhage.